Improving macroeconomic conditions and increased political certainty point to a favourable outlook for IPO activity across ...
In 2009, the outlook for Eli Lilly was uncertain. But a dogged commitment to R&D has shored up its future and positioned it at the forefront of pharma innovation. Pursuing organic growth is often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback